Novacyt (ALNOV.PA)

Executive Summary

Novacyt is an international molecular diagnostics company focused on genomic medicine, with applications in reproductive health, precision medicine, and infectious disease. The company offers a broad portfolio of integrated technologies, including assays, workflows, and instrumentation. Despite being relatively small with a market cap around €65 million, Novacyt has established itself as a leader in niche areas such as reproductive health and precision medicine. Following the decline in COVID-19 testing demand, the company is strategically pivoting toward non-COVID molecular diagnostics, leveraging its proprietary platforms and expertise. Its strategy emphasizes expanding product pipelines, entering new geographic markets, and forging partnerships to drive growth. With a lean operational structure, Novacyt is well-positioned to capitalize on the growing demand for personalized medicine and advanced diagnostic solutions. Looking ahead, Novacyt's near-term prospects depend on successful product launches, regulatory approvals, and strategic collaborations. The company is expected to introduce new assays for oncology and reproductive health, with several potential catalysts on the horizon. Key risks include intense competition, regulatory hurdles, and reliance on a limited number of products. However, successful execution could lead to significant valuation upside. Investors should monitor upcoming milestones, particularly in CE-IVDR certification and partnership announcements. Overall, Novacyt represents a speculative opportunity with moderate conviction, driven by its innovative pipeline and market positioning.

Upcoming Catalysts (preview)

• Q4 2026CE-IVDR certification for a novel oncology molecular diagnostic assay70% success
• H2 2026Strategic partnership with a major pharmaceutical company for companion diagnostics development40% success
• Q3 2026Launch of a non-invasive prenatal testing (NIPT) product in key European markets60% success